In patients with IBD linked with primary sclerosing cholangitis and receiving optimized anti-TNF therapy for IBD, the use of cholestyramine induced a rapid and sustained drop in fecal calprotectin levels [139]. This evidence concerns the gene TNF and inflammatory bowel disease.